Nycomed Amersham Imaging
This article was originally published in The Gray Sheet
Executive SummaryFirm commences Phase I clinical trial of lung imaging agent NC100182 to document safety following investigational new drug approval. Based on "spin signal" technology, the firm "is hopeful that potential applications will include use in patients with asthma, cystic fibrosis, chronic obstructive lung disease such as emphysema and patients undergoing transplantation and lung volume reduction surgery." The technology was derived in part through the acquisition of Magnetic Imaging Technologies last year. The Phase I trial is expected to close in the fall and a Phase II trial examining the agent could begin in early 2001
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.